ClinicalTrials.gg
CompletedNCT03272009Updated Aug 21, 2018

Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects

A Phase 1 interventional study of EYP001a and Placebo in Hepatitis B, Chronic, sponsored by Enyo Pharma. Completed at 9 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-08-21.

Sponsored by Enyo Pharma · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
73
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic — 1 open to participants now, 1 under way, none of them phase 3. peginterferon alfa-2a · Hepatitis B, Chronic.

Enrollment
40th of 59
73 · median 114
Started
2017
with 1 other
Phase 1
6 of 59
1 open now
Registered
57th of 59
by date
Lead sponsor
2 of 59
Enyo Pharma

Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, this one is the 40th largest by enrollment, is one of 2 that started in 2017, is one of 6 in phase 1, and was the 57th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

1 of the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic is open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About peginterferon alfa-2a

peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

Bile acids regulating farnesoid X receptor (FXR) interact with hepatitis B virus replication. EYP001a is a selective, synthetic FXR agonist under development for the treatment of hepatitis B.

This Phase 1b study is designed primarily to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of EYP001a in chronically HBV infected subjects.

Read the detailed description

This is a multicenter, randomized, double-blind, placebo-controlled two-part trial.

In Part A, EYP001a will be administered as 29 days monotherapy. Three dose-levels and 2 dosing regimens of EYP001a will be explored against placebo. The design also includes an open-label standard of care Entecavir monotherapy arm (comparator). Subjects will be randomly assigned to one of the 6 treatment arms:

  • Treatment A: oral EYP001a
  • Treatment B: oral EYP001a
  • Treatment C: oral EYP001a
  • Treatment D: oral EYP001a
  • Treatment E: oral placebo
  • Treatment F: oral Entecavir

In Part B, EYP001a or placebo will be administered as 29 days combination therapy with the standard of care Peg-IFNα2a. Subjects will be randomly assigned to one of the 3 treatment arms:

  • Treatment G: oral EYP001a plus open label Peg-INFα2a administered as subcutaneous injection
  • Treatment H: oral EYP001a plus open label Peg-INFα2a administered as subcutaneous injection
  • Treatment I: oral placebo plus open label Peg-INFα2a administered as subcutaneous injection

Subjects enrolled in Part A are eligible for participation in Part B.

Participation will include a 40 day screening period, a 29 day treatment period and a 6 day follow-up evaluation period. For subjects who participate in both Parts A and B, a 14 washout period between Parts A and B will be included.

The safety and tolerability of EYP001a will be assessed by evaluating physical examinations, vital signs, ECGs, clinical laboratory parameters, and adverse events.

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have given voluntary written ;
  2. Have a documented medical history of chronic infection (within 12 months of screening visit), both results:

    • Documented positive hepatitis B surface antigen (HBsAg) and
    • Documented HBV DNA > 1000 IU/mL
  3. Is anti-HBV treatment naive or treatment experienced (see also exclusion criterion #3).
  4. Gender: male or female.
  5. Age: 18 to 65 years inclusive.
  6. (BMI): 17.0-35.0 kg/m2 inclusive.
  7. Has clinical chemistry, hematology, coagulation and urinalysis tests within normal, allowable limits (with the exception of [ALT]); see inclusion criterion #10); if there is an out of range value, the result must be considered clinically non-significant by the investigator in order to be eligible.
  8. Vital signs after at least 5 minutes resting in supine position at screening within the following ranges:

    • systolic blood pressure: between 90 mm Hg and 145 mm Hg
    • diastolic blood pressure: between 45 mm Hg and 90 mm Hg
    • heart rate: between 40 bpm and 100 bpm
  9. Have no abnormal 12-lead automatic (ECG) (incomplete right bundle branch block can be accepted) at screening: PR interval between 120 ms -and 210 ms, QRS-duration \< 120 ms, -interval (Fridericia's) ≤ 450 msec.
  10. ALT at screening ≤ 5 x (ULN).
  11. Agrees to abstain from all medication, including non-prescription and prescription medication for 28 days prior to the Day 1 study visit, except for authorized medications (such as hormonal for females, vitamins prescribed per label dosages and paracetamol). On a case-by-case basis, regular co-medication either as defined on the medication exception list or as documented by written approval from the sponsor as acceptable prior to randomization, will not be considered as a deviation from this criterion.
  12. At screening, females must be non-pregnant and non-lactating, or of non- (either surgically sterilized or physiologically incapable of becoming pregnant, or at least 1 year [amenorrhea duration of 12 consecutive months); non-pregnancy will be confirmed for all females by a pregnancy test conducted at screening and at follow-up visit.
  13. Female subjects of child-bearing potential, with a fertile male sexual partner, should be willing to use adequate contraception from screening until 90 days after the follow-up visit. Adequate contraception is defined as using hormonal contraceptives or an intrauterine device combined with at least 1 of the following forms of contraception: a diaphragm or cervical cap, or a condom. Also, total abstinence, in accordance with the lifestyle of the subject, is acceptable.
  14. Male subjects, if not surgically sterilized, should be willing to use adequate contraception and not donate sperm from the Day 1 visit to the clinical research centre until 90 days after the follow-up visit. Adequate contraception for the male subject (and his female partner) is defined as using hormonal contraceptives or an intrauterine device combined with at least 1 of the following forms of contraception: a diaphragm or cervical cap, or a condom. Also, total abstinence, in accordance with the lifestyle of the subject is acceptable.
  15. At screening, has no recent (\<3 months) history of any clinically significant conditions, which, in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results.
  16. Willingness to abstain from alcohol from 48 hours prior to each study visit to the clinical research centre.

Exclusion criteria

Exclusion Criteria:

  1. Employee of a CRO participating in this study or the Sponsor.
  2. Has certain or probable compensated liver cirrhosis documented by at least 2 of the following:

    1. Optional assessment: has documented liver histology Metavir score (F4), Ishak >5 or Scheuer (F4)
    2. Mandatory assessment: has presence or history of ascites, spontaneous bacterial peritonitis, esophageal varices, hepatic encephalopathy
    3. Mandatory assessment: count below 90,000/uL within 12 months of screening visit
    4. Optional assessment: positive indirect blood test of APRI or FIB4 or positive direct blood test Fibrosure, Fibrotest, or FibroSpect within 12 months of screening visit
    5. Optional assessment: has positive elastography within 6 months of screening visit (Fibroscan or Shearwave Aixplorer)
    6. Optional assessment: has abnormal liver imaging (CT/US/MRI) consistent with a lobular/nodular liver and cirrhosis or indirect signs of portal hypertension.
  3. Subject is treatment experienced AND currently on anti-HBV treatment during the 30 days (or 5 half-lives of the considered anti-HBV drug, whichever is longer) before the first product administration and until the last study visit.
  4. Co-infection with active virus (HCV, except for patients with sustained viral response SVR, who can be included).
  5. Co-infection with (HIV) Note: hepatitis D virus (HDV) status is not required for randomization and if not available can be established during the Day 1 visit with baseline PD virology assessments.
  6. Receives or plans to receive systemic or immunomodulating medications (e.g. IFN) during the study or ≤ 4 months prior to the first investigational product administration.
  7. Has immunosuppression from, but not limited to immunodeficiency conditions such as common variable hypogammaglobulinemia.
  8. Clinical diagnosis of substance abuse during ≤ 12 months prior to screening with narcotics or cocaine or with alcohol (regular consumption > 21 units/week [men] and > 14 units/week [women]; 1 unit = 1⁄2 pint of beer, 25 mL shot of 40% spirit or a 125 mL glass of wine. Expressed in g/day: > 30 g/day [men] and > 20 g/day [women]).
  9. Has a positive drug urine screen (cocaine, phencyclidine, amphetamines (incl. methamphetamines), opiates (incl. heroin, codeine and morphine), benzodiazepines, barbiturates, methadone or alcohol screen. Subjects who admit the occasional use of cannabis will not be excluded as long as they are able to abstain from cannabis when they are assessed at study visits.
  10. Has any known pre-existing medical or psychiatric condition that could interfere with the subject's ability to provide or participate in study conduct, or that may confound study findings.
  11. Has a history of long syndrome.
  12. Has a history of clinically significant gastrointestinal disease, especially peptic ulcerations, gastrointestinal bleeding, ulcerative colitis, Crohn's disease or Inflammatory Bowel Syndrome, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, or cardiovascular disease or any other condition which, in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results.
  13. Has participated in any drug study within 40 days prior to the first drug administration in the current study. Note: Part A participation to this study is acceptable and not an exclusion criteria when considering eligibility for Part B, under the condition that follow-up visit of Part A has been completed and no investigational product related SAEs have occurred during Part A.
  14. Has an uncontrolled ongoing illness at screening (e.g., active viral infection).
  15. Has had major surgery within 30 days prior to the first drug administration, or within 6 months for gastrointestinal surgery prior to the first drug administration.
  16. Has a history of relevant drug and/or food allergies.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    Treatment A

    oral EYP001a

    Drug: EYP001a

  • Experimental
    Treatment B

    oral EYP001a

    Drug: EYP001a

  • Experimental
    Treatment C

    oral EYP001a

    Drug: EYP001a

  • Experimental
    Treatment D

    oral EYP001a

    Drug: EYP001a

  • Placebo comparator
    Treatment E

    oral placebo

    Drug: Placebo

  • Active comparator
    Treatment F

    oral Entecavir

    Drug: Entecavir

  • Experimental
    Treatment G

    oral EYP001a plus subcutaneous injection of Peg-INFα2a

    Drug: EYP001a · Drug: peg-interferon alfa-2a

  • Experimental
    Treatment H

    oral EYP001a plus subcutaneous injection of Peg-INFα2a

    Drug: EYP001a · Drug: peg-interferon alfa-2a

  • Placebo comparator
    Treatment I

    oral placebo plus subcutaneous injection of Peg-INFα2a

    Drug: Placebo · Drug: peg-interferon alfa-2a

Interventions

  • Capsules administered orally. Number of morning and evening capsules depending on treatment arm

  • DrugPlacebo

    Placebo capsules for oral administration, identical in appearance to the EYP001a capsules

  • Tablets administered orally

  • Ready-to-Use pre-filled syringes for subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Type and frequencies of adverse events

    Time frame: Day 1 through Day 35

Secondary outcomes

  1. Maximum plasma concentration (Cmax) of EYP001

    Time frame: Day 1 through Day 35

  2. Time to reach maximum concentration (Tmax) after EYP001 administration

    Time frame: Day 1 through Day 35

  3. Area under the concentration-time curve from time 0 to last measurable concentration (AUC0-6h) of EYP001

    Time frame: Day 1 through Day 35

  4. Bile acid precursor C4 (7αhydroxy-4-cholesten-3-one)

    Time frame: Day 1 through Day 35

  5. Fibroblast growth factor 19 (FGF19)

    Time frame: Day 1 through Day 35

07

Study locations

9 sites
  • Scientia Clinical Research Limited
    Sydney, New South Wales 2031, Australia
  • Linear Clinical Research Limited
    Perth, Western Australia 6009, Australia
  • Academic Medical Centre (AMC)
    Amsterdam, Netherlands
  • Erasmus MC
    Rotterdam, Netherlands
  • Klinika Chorób Zakaźnych I Hepatologii UMB
    Białystok, Poland
  • Klinika Chorób Zakaźnych
    Kielce, 25-317, Poland
  • HepID
    Lublin, Poland
  • King Chulalongkorn Memorial Hospital
    Bangkok, 10330, Thailand
  • Hospital for Tropical Diseases
    Bangkok, 10400, Thailand
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Jul 2018, 10 months.

Of 73 industry-sponsored phase 1 interventional studies under Hepatitis B, Chronic, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's 10 months is below that.

Counting every sponsor, half of 81 studies reached it within 16 months; a quarter within 6 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2017
First posted
Sep 5, 2017
StartActual
Sep 21, 2017
Primary completionActual
Jul 30, 2018
CompletionActual
Jul 30, 2018
Last update
Aug 21, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03272009
Lead sponsor
Enyo Pharma
Collaborators
CPR Pharma Services Pty Ltd, Australia
Responsible party
Sponsor
First posted
Sep 5, 2017
Start date
Sep 21, 2017
Primary completion
Jul 30, 2018
Completion
Jul 30, 2018
Last update
Aug 21, 2018

Study contacts

Henk W Reesink, MD
principal investigator · Academic Medical Centre AMC Amsterdam
Stephan Riordan
principal investigator · Scientia Clinical Research Limited Sydney

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: EYP001A · Peginterferon alfa-2a

Start the discussion